Clinical Use of the Interferon Inducer IIBI in Patients with Refractory Hodgkin’s Lymphoma

Daniyar Aspetov, Almaty, Kazakhstan, Maria Omarova, Lyazzat Zh. Orakbay, R K Karakulov, Kairat Doskhozhayev, Bayan Zhumatova, Meruyert Chazhayeva

2015

Closed access Metadata (CSL-JSON)

DOI 10.21103/article5(4)_oa9

Data confidence 70 medium

How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

This study evaluated the effects of the immunobiological preparation "Interferon inducer bacterial liquid" (IIBI) combined with chemoradiotherapy (CRT) in patients with refractory Hodgkin's lymphoma (HL) are presented.The clinical application of IIBI increases the efficacy of treatment.IIBI in combination with CRT induces the production of highly active endogenous IFNα/β, provides a marked regression of the affected lymph nodes in a short period (within 7 to 10 days) of treatment, relieves B symptoms, and increases by 2 times the length of remission in patients with refractory HL. (Int J Biomed.2015; 5(4):214-218.)